<DOC>
	<DOCNO>NCT00004183</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness capecitabine treat patient malignant mesothelioma .</brief_summary>
	<brief_title>Capecitabine Treating Patients With Malignant Mesothelioma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate , overall survival , failure free survival patient malignant mesothelioma treat capecitabine . II . Determine toxicity regimen patient . OUTLINE : This multicenter study . Patients receive oral capecitabine twice daily day 1-14 . Treatment repeat every 3 week maximum 6 course absence disease progression unacceptable toxicity . Patients follow every 2 month 1 year , every 3 month 2 year annually thereafter . PROJECTED ACCRUAL : A total 25 patient accrue study within 7-9 month .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove malignant mesothelioma amenable potentially curative radiotherapy surgery Epithelial , sarcomatoid , mixed subtype Any site origin allow include , limited , follow : Pleura Peritoneum Pericardium Tunica vaginalis Measurable disease At least one lesion accurately measure least one dimension Lesion least 20 mm large diameter conventional technique least 10 mm spiral CT scan The following consider measurable disease : Bone lesion Leptomeningeal disease Ascites Pleural/pericardial effusion Abdominal mass confirm followed imaging technique Cystic lesion Tumor lesion locate previously irradiate area PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 0 1 Life expectancy : Not specify Hematopoietic : Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGOT great 2.5 time ULN Renal : Creatinine great 1.5 time ULN Other : Not pregnant nursing Fertile patient must use effective contraception No active second malignancy except nonmelanomatous skin cancer Not consider active second malignancy : Therapy complete Less 30 % risk relapse accord physician No malabsorption syndrome PRIOR CONCURRENT THERAPY : Biologic therapy : Concurrent epoetin alfa allow Chemotherapy : No prior systemic cytotoxic chemotherapy malignant mesothelioma Prior intrapleural cytotoxic sclerosing agent ( include bleomycin ) allow No concurrent chemotherapy Endocrine therapy : No concurrent hormonal therapy except follow : Steroids administer adrenal failure Hormonal therapy administer nonmalignant condition ( e.g. , insulin diabetes ) Intermittent use dexamethasone antiemetic Radiotherapy : At least 4 week since prior radiotherapy Prior irradiation symptomatic lesion allow measurable disease outside radiation port No concurrent radiotherapy Surgery : At least 2 week since prior major surgery Other : No concurrent leucovorin calcium folinic acid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>localize malignant mesothelioma</keyword>
	<keyword>advanced malignant mesothelioma</keyword>
	<keyword>recurrent malignant mesothelioma</keyword>
	<keyword>epithelial mesothelioma</keyword>
	<keyword>sarcomatous mesothelioma</keyword>
</DOC>